Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pieper, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pieper, J.
American Journal of Health-System Pharmacy, Vol 60, Issue suppl_2, S9-S14
Copyright © 2003 by American Society of Health-System Pharmacists

Articles

Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety

JA Pieper


The pharmacokinetics, efficacy, and safety of niacin and its various formulations are discussed. Niacin has been used for decades for the treatment of dyslipidemia because of its favorable effects on all lipoprotein parameters. Niacin significantly increases high-density lipoprotein cholesterol (HDL-C) more than any other available agent and reduces total cholesterol, low-density lipoprotein cholesterol (LDL-C), lipoprotein (a), and triglycerides. Niacin is currently available in immediate-release (IR), sustained-release (SR), and extended-release (ER) formulations that differ in their dissolution, pharmacokinetic, efficacy, and safety profiles. Important drawbacks to niacin therapy such as cutaneous flushing, associated with IR niacin, and hepatotoxicity, associated with SR niacin, have historically limited its use. The adverse effect profiles of the different niacin formulations can be explained by differences in their dissolution and absorption rates and metabolic disposition, which result in production of metabolites associated with the respective adverse effects. The ER niacin formulation, with an intermediate dissolution rate between the dissolution rates of IR and SR niacin, demonstrates reduced rates of cutaneous flushing compared with IR niacin and hepatotoxic effects compared with SR niacin. Pharmacists need to be familiar with the pharmacokinetics, efficacy, and safety of available niacin formulations so that they can optimally educate both patients and health care providers on the differences among niacin formulations, counsel on the proper selection of a niacin product, and provide strategies for improving tolerance and adherence to therapy.
 



This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
R. M. Menon, M. A. Gonzalez, M. H. Adams, D. S. Tolbert, J. H. Leu, and E. A. Cefali
Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites
J. Clin. Pharmacol., June 1, 2007; 47(6): 681 - 688.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
I. O. Poon, D. S.-L. Chow, and D. Liang
Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products.
Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2128 - 2134.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.